# Patent

## Title
Compositions for improving migration potential of stem cells

## Abstract

The present invention relates to a composition for improving the migration potential of a stem cell, a method for evaluating the migration potential of a stem cell and a method for screening an adjuvant of cell therapy improving the migration potential of a stem cell. The present invention may be effectively used for enhancing the efficacy of neurological disease-treatment by inducing therapeutic stem cells to migrate efficiently to the lesion site.

## Background
Cross-Reference to Related Applications
This application is the U.S. national stage filing under 35 U.S.C. § 371 of international application PCT/KR2010/007152, filed Oct. 19, 2010, which claims benefit of Korean Patent Application No. 10-2009-0099146, filed Oct. 19, 2009.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to compositions for improving migration potential of stem cells
2. Background of Technique
Adult stem cells derived from different types of tissues have different differentiation capacities and functional properties which may make them more or less effective for treating individual disorders (1). Clarification of these properties for each stem cell origin is necessary for the creation of clinical guidelines to aid in the selection of the optimal stem cell origin for patient treatment.
Mesenchymal stromal cells (MSCs) can improve the recovery of cerebral ischemia either by neuronal differentiation and replacement of damaged, or by providing neuroprotection to damaged neurons after migrating to the lesion site. The key factors governing the migratory capacity of stem cells, however, are largely unknown. Autologous MSCs are generally preferred for therapeutic transplantation because they are not subject to immune rejection. However, if the differentiation or migratory capacities of autologous MSCs lacks or are compromised, a universal donor approach should be adopted as an alternative. Therefore, it had been an important subject to identify the factors involved in stem cell migration.
Throughout this application, various publications and patents are referred and citations are provided in parentheses. The disclosures of these publications and patents in their entities are hereby incorporated by references into this application in order to fully describe this invention and the state of the art to which this invention pertains.
SUMMARY OF THE INVENTION
The present inventors have made intensive studies to elevate the efficacy of stem cell therapy by improving the migration potential of implanted stem cells to the lesion site. As results, we have discovered the factor involved in migration of the stem cells.
Accordingly, it is an object of this invention to provide a composition for improving the migration potential of a stem cell.
It is another object of this invention to provide a stem cell transformed with the composition of the present invention.
It is still another object of this invention to provide a composition for treating neurological diseases comprising the stem cell of the present invention.
It is further object of this invention to provide a method for evaluating the migration potential of a stem cell.
It is still further object of this invention to provide a method for screening an adjuvant of cell therapy improving the migration potential of a stem cell to treat neurological diseases.
Other objects and advantages of the present invention will become apparent from the following detailed description together with the appended claims and drawings.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 represents the migratory capacity of MSCs depends on their origin. FIG. 1a shows the migratory activity of Ferumoxides-labeled mesenchymal stromal cells (MSCs) from various origins, including amyotrophic lateral sclerosis patient-derived MSC (ALSMSC), C-MSC (purchased from Cambrex), human umbilical cord-derived MSC (hUC-MSC), and umbilical cord blood-derived MSC (UCB-MSC) in the ischemic stroke model of rat brain by in vivo MR imaging. MR imaging shows that C-MSC, hUC-MSC, and UCB-MSC, which were implanted into the contralateral sides of ischemia damaged brains, migrated to the lesion site, but ALS-MSCs did not. FIG. 1b shows that the ALS-MSC did not migrate 35 days after implantation. FIG. 1c shows the result of in vitro cell migration assays indicating that C-MSC, hUC-MSC, and UCB-MSC had migratory capacity, but ALS-MSCs did not.
FIG. 2 represents expression levels of β-PIX and migration-associated factors in MSCs from different origins. β-PIX and some migration-associated gene expression levels were lower in ALS-MSC than C-MSC as assessed by quantitative PCR array (FIG. 2a). Expression levels of mRNA (FIG. 2b) and protein (FIGS. 2c and 2d) were lowest in ALS-MSC.
FIG. 3 represents that the alteration of β-PIX expression affects migratory capacity. Knockdown of β-PIX mRNA and protein was induced in C-MSC with shRNA (FIG. 3a). β-PIX over-expression in ALS-MSC with β-PIX-Lentivirus increased ALS-MSC migratory capacity (FIGS. 3b and 3c). β-PIX knockdown decreased C-MSC migratory capacity (FIG. 3c).
FIG. 4 shows that In vivo migratory capacity of MSCs depends upon expression levels of β-PIX. The migration of human MSCs to lesion sites in the rat stroke model was assessed with MR imaging. β-PIX depleted C-MSCs did not migrate to lesion sites, while mock treated C-MSC did (FIG. 4a). β-PIX over-expression restored the ability of ALS-MSCs to migrate to lesion sites (FIG. 4b).
FIG. 5 represents the confirmation of migration of implanted MSCs with MR imaging and immunohistochemistry. Considering the results of the MPGR image and the immunohistochemical staining, migration of MSCs to the contralateral lesion site from the primary injection site is found as migratory spots in the MPGR image
FIG. 6 represents the alteration of behavioral functions after the implantation of MSCs depending on their origin. A decrease in the neurologic deficit score (NDS) indicates an improvement in behavioral functions. As shown in this figure, there was no difference between the five groups prior to implantation, but the NDS was significantly lower in the C-MSC, hUC-MSC, and UCB-MSC groups (N=10 in each group) than in the ALS-MSC group (N=10) from 7 days after implantation although statistically significant difference was shown from 21 days after implantation. In other words, C-MSCs, hUC-MSCs, and UCB-MSCs significantly improved behavioral functions of ischemic stroke rats but ALS-MSCs did not. [*p<0.05 when compared with the PBS group, Wilcoxon Scores (Rank Sums) Test after Kruskal-Wallis Test].
FIG. 7 represents the result of quantitative PCR assay to evaluate the difference of migration associated genes between ALS-MSCs and C-MSCs
FIG. 8 represents the result of the evaluation of surface marker expression of ALS-MSCs, UCB-MSCs, hUC-MSCs, and C-MSCs. The cells were characterized by staining with the following anti-human antibodies: CD45-phycoerythrin (PE), CD44-fluorescein isothiocyanate (FITC) (DakoCytomation, Denmark), CD73-PE (BD Pharmingen, CA, USA), CD34-PE, CD29-FITC, CD49C-PE, CD54-FITC, CD105-FITC, CD106-FITC, HLA-DR-FITC, and PE- and FITC-conjugated isotype controls (Serotec, UK). After staining, cells were analyzed using flow cytometry (Calibur, Calif., USA).1 On flow cytometric analysis of surface marker expression, ALS-MSCs, UCB-MSCs, hUC-MSCs, and C-MSCs commonly demonstrate a CD45-CD34-CD29+CD73+CD105+CD44+HLA-DR-phenotype. These surface markers are not different in β-PIX knockdowned C-MSCs and β-PIX overexpressed ALS-MSCs.
FIG. 9 represents the comparison of behavioral functions between β-PIX knockdowned and vehicle C-MSCs. The neurologic examination was performed daily as above described after the implantation of β-PIX knockdowned and vehicle C-MSCs. As shown in this figure, there was no improvement in behavioral functions of the ischemic stroke rats (N=10) implanted with β-PIX knockdowned C-MSCs when compared with the rats (N=10) implanted with vehicle C-MSCs. In other words, β-PIX knockdowned C-MSCs did not improve behavioral functions of ischemic stroke rats but vehicle C-MSCs did. [*p<0.05 when compared with the PBS group, Wilcoxon Scores (Rank Sums)].
FIG. 10 represents comparison of neurotrophic factors. When compared with C-MSCs, concentrations of SDF-1α (A) and VEGF (B) were significantly decreased in culture supernatant of ALS-MSCs but concentration of BDNF (C) was not. The level of these neurotrophic factors is not affected by genetic modulation of β-PIX.
FIG. 11 shows the vector map of pLenti6/V5-D-TOPO used in cloning β-PIX.



DETAILED DESCRIPTION OF THE INVENTION
In one aspect of this invention, there is provided a composition for improving the migration potential of a stem cell, which comprises as an active ingredient a gene delivery system comprising a nucleotide encoding β-PIX having the amino acid sequence of SEQ ID NO:2.
In another aspect of this invention, there is provided a method for improving the migration potential of a stem cell, comprising contacting to the stem cell a gene delivery system comprising a nucleotide sequence encoding β-PIX having the amino acid sequence of SEQ ID NO:2.
The present inventors have made intensive studies to elevate the efficacy of stem cell therapy by improving the migration potential of implanted stem cells to the lesion site. As results, we have discovered that β-PIX is a crucial factor involved in migration of stem cells.
The term “gene delivery system” as used herein, refers to any forms of carriers that harbor and transport exogenous nucleic acid molecules to a target cell or tissue. As used herein, “delivery” is used interchangeably with “transduction”. At the level of tissue, the term “delivery” is used interchangeably with “spread”. Therefore, the term “gene delivery system” may also be written as “gene transduction system” or “gene spread system”.
The gene delivery system of this invention comprises any of gene delivery system used in gene therapy by those skilled in the art, preferably, plasmid, adenovirus (Lockett L J, et al., Clin. Cancer Res., 3:2075-2080(1997)), adeno-associated virus (AAV, Lashford L S., et al., Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), retrovirus (Gunzburg W H, et al., Retroviral vectors. Gene Therapy Technologies, Applications and Regulations Ed. A. Meager, 1999), lentivirus (Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999)), herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA, 92:1411-1415(1995)), vaccinia virus (Puhlmann M. et al., Human Gene Therapy, 10:649-657(1999)) liposome ((Methods in Molecular Biology, Vol 199, S. C. Basu and M. Basu (Eds.), Human Press 2002)) or niosome. Most preferably, the gene delivery system of this invention is constructed by incorporating the β-PIX-encoding nucleotide sequence to lentiviruses. The Lentivirus is a type of retroviruses and enables transported genes to be expressed for long by integration with the stem cell genome. Furthermore, it may be infected to the fully differentiated cells as well as dividing cells.
To prepare the gene delivery system of the present invention, it is preferred that the β-PIX-encoding nucleotide sequence is inserted into an appropriate expression construct. Preferably, the β-PIX-encoding nucleotide sequence is operatively linked to a promoter in the expression construct. The term “operatively linked” refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.
According to the present invention, the promoter linked to the β-PIX gene, without limitation, is operable in, preferably, animal, more preferably, mammalian cells, to control transcription of the β-PIX gene. The promoter includes the promoters derived from the genome of mammalian cells or from mammalian viruses, for example, CMV (cytomegalovirus) promoter, the adenovirus late promoter, the vaccinia virus 7.5K promoter, SV40 promoter, HSV tk promoter, RSV promoter, EF1 alpha promoter, metallothionein promoter, beta-actin promoter, human IL-2 gene promoter, human IFN gene promoter, human IL-4 gene promoter, human lymphotoxin gene promoter and human GM-CSF gene promoter. Most preferably, the promoter is CMV promoter.
According to a preferred embodiment of the present invention, the polyadenylation sequence linked to the β-PIX gene comprises, but not limited to, bovine growth hormone terminator (Gimmi, E. R., et al., Nucleic Acids Res., 17:6983-6998(1989)), SV40-derived polyadenylation sequence (Schek, N., et al., Mol. Cell. Biol., 12:5386-5393(1992)), HIV-1 polyA (Klasens, B. I. F., et al., Nucleic Acids Res., 26:1870-1876(1998)), β-globin polyA (Gil, A., et al., Cell, 49:399-406(1987)), or poliomavirus polyA (Batt, D. B. and G. G. Carmichael, Mol. Cell. Biol., 15:4783-4790(1995)).
The term “migration potential” as used herein, refers to the migratory ability of therapeutic cells to migrate to lesion sites.
According to the present invention, the amino acid sequence of SEQ ID NO:2 encoded by the β-PIX gene is very useful for improving neurological function by cell therapy through enhancing the migration potential of stem cells to lesion sites.
According to a preferred embodiment, the nucleotide sequence of this invention comprises a nucleotide of SEQ ID NO:1.
The nucleotide sequence of SEQ ID NO:1 used in the present invention is the β-PIX gene. Little has been known about biological functions of the β-PIX gene in stem cell biology. Instead, it has established functions in T cell chemotaxis across reactive barriers (3), cancer cell migration (4), and neurite outgrowth (5).
The present invention may be applied to any of stem cells including, but not limited to, embryonic stem cells, adult stem cells, induced pluripotent stem cells, embryonic germ cells, embryonic carcinoma cells, preferably, multipotent adult stem cells, and more preferably, a mesenchymal stem cell (MSC).
In the present invention, the stem cell is contacted to the gene delivery system comprising a nucleotide sequence encoding β-PIX having the amino acid sequence of SEQ ID NO:2, such that the migration potential of the stem cell is dramatically increased.
The contacting of stem cells to the gene delivery system is to transfect stem cells with the gene delivery system. The transfection may be performed in accordance with conventional techniques known to those skilled in the art. For example, stem cells may be incubated in a media for a sufficient period of time with suitable viral vectors carrying the β-PIX gene. The media for stem cells includes, but not limited to, Eagles's MEM (Eagle's minimum essential medium, Eagle, H. Science 130:432(1959)), α-MEM (Stanner, C. P. et al., Nat. New Biol. 230:52(1971)), Iscove's MEM (Iscove, N. et al., J. Exp. Med. 147:923(1978)), 199 medium (Morgan et al., Proc. Soc. Exp. Bio. Med., 73:1(1950)), CMRL 1066, RPMI 1640 (Moore et al., J. Amer. Med. Assoc. 199:519(1967)), F12 (Ham, Proc. Natl. Acad. Sci. USA 53:288(1965)), F10 (Ham, R. G. Exp. Cell Res. 29:515(1963)), DMEM (Dulbecco's modification of Eagle's medium, Dulbecco, R. et al., Virology 8:396(1959)), mixture of DMEM and F12 (Barnes, D. et al., Anal. Biochem. 102:255(1980)), Way-mouth's MB752/1 (Waymouth, C. J. Natl. Cancer Inst. 22:1003(1959)), McCoy's 5A (McCoy, T. A., et al., Proc. Soc. Exp. Biol. Med. 100:115(1959)) and MCDB series (Ham, R. G. et al., In Vitro 14:11(1978)).
In still another aspect of this invention, there is provided a stem cell transformed with the composition of the present invention.
As the composition for improving the migration potential of stem cells and applicable stem cells are mentioned hereinabove, they are omitted herein to avoid undue redundancy.
In still another aspect of this invention, there is provided a composition for treating neurological diseases comprising the stem cell of the present invention.
The composition of this invention may be provided as a pharmaceutical composition. The pharmaceutical composition of this invention includes a pharmaceutically acceptable carrier besides the active ingredient compound. The pharmaceutically acceptable carrier contained in the pharmaceutical composition of the present invention, which is commonly used in pharmaceutical formulations, but is not limited to, includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, rubber arable, potassium phosphate, arginate, gelatin, potassium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oils. The pharmaceutical composition according to the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent and a preservative. Details of suitable pharmaceutically acceptable carriers and formulations can be found in Remington's Pharmaceutical Sciences (19th ed., 1995).
The pharmaceutical composition according to the present invention may be administered via the routes used commonly in gene therapy and preferably, administered parenterally, i.e., by intravenous, intraperitoneal, intramuscular, subcutaneous, or local administration. For example, the pharmaceutical composition may be administered intrathecally or intracerebroventricularly.
A suitable dosage amount of the pharmaceutical composition of the present invention may vary depending on pharmaceutical formulation methods, administration methods, the patient's age, body weight, sex, pathogenic state, diet, administration time, administration route, an excretion rate and sensitivity for a used pharmaceutical composition and physicians of ordinary skill in the art can determine an effective amount of the pharmaceutical composition for desired treatment. Generally, a daily dosage of the pharmaceutical composition of the present invention comprises 1×102-1×1010 cells.
According to the conventional techniques known to those skilled in the art, the pharmaceutical composition of the present invention may be formulated with pharmaceutically acceptable carrier and/or vehicle as described above, finally providing several forms a unit dose form and a multi-dose form. Non-limiting examples of the formulations include, but not limited to, a solution, a suspension or an emulsion in oil or aqueous medium, an extract, an elixir, a powder, a granule, a tablet and a capsule, and may further comprise a dispersion agent or a stabilizer.
The diseases treated by the composition of the present invention include any of neurological diseases caused by pathological or physical demage of nervous tissues, and preferably, Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), cerebral ischemia, cerebral hemorrhage, spinal cord injury, motor neuron disease, demyelinating disease, Huntington's disease, and more preferably, ischemic stroke.
In still another aspect of this invention, there is provided a method for evaluating the migration potential of a stem cell, comprising measuring the expression level of the nucleotide sequence of SEQ ID NO:1 in a biological sample.
The term “biological sample” as used herein refers to materials containing stem cells with biological activities to be analyzed.
The measurement of the expression level of the nucleotide of SEQ ID NO:1 may be performed by any of methods for evaluating the gene expression level generally known to those skilled in the art. For example, it may be performed through measuring mRNA level transcribed by DNA molecules, or measuring protein level translated by the mRNA.
The measurement of mRNA expression level may be carried out by amplification reaction using mRNA in the sample as template, and primers binding to mRNA or cDNA. For obtaining mRNA molecules, total RNA is isolated from samples. The isolation of total RNA may be performed by various methods (Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press (2001); Tesniere, C. et al., Plant Mol. Biol. Rep., 9:242 (1991); Ausubel, F. M. et al., Current Protocols in Molecular Biology, John Willey & Sons (1987); and Chomczynski, P. et al., Anal. Biochem. 162:156 (1987)). For example, total RNA in cells may be isolated using Trizol. Afterwards, cDNA molecules are synthesized using mRNA molecules isolated and then amplified. Since total RNA molecules used in the present invention are isolated from human samples, mRNA molecules have poly-A tails and converted to cDNA by use of dT primer and reverse transcriptase (PNAS USA, 85:8998(1988); Libert F, et al., Science, 244:569(1989); and Sambrook, J. et al., Molecular Cloning. A Laboratory Manual, 3rd ed. Cold Spring Harbor Press (2001)). cDNA molecules synthesized are then amplified by amplification reactions.
A variety of DNA polymerases can be used in the extension step of the present methods, which includes “Klenow” fragment of E. coli DNA polymerase I, a thermostable DNA polymerase, and bacteriophage T7 DNA polymerase. Preferably, the polymerase is a thermostable DNA polymerase which may be obtained from a variety of bacterial species, including Thermus aquaticus (Taq), Thermus thermophilus (Tth), Thermus filiformis, Thermis flavus, Thermococcus literalis, and Pyrococcus sp. Most preferably, the polymerase obtained from Pyrococcus sp may be used, and the present inventors used PyrobestTM DNA polymerase (TaKaRa, Japan).
When a polymerization reaction is being conducted, it is preferable to provide the components required for such reaction in excess in the reaction vessel. Excess in reference to components of the extension reaction refers to an amount of each component such that the ability to achieve the desired extension is not substantially limited by the concentration of that component. It is desirable to provide to the reaction mixture an amount of required cofactors such Mg2+, dATP, dCTP, dGTP, and dTTP in sufficient quantity to support the degree of the extension desired. All of the enzymes used in polymerization reaction may be in active state at equivalent reaction conditions. In fact, buffers give the optimal reaction conditions to all enzymes. Therefore, the polymerization process of the present invention can be performed in a single reactant without change of condition such as addition of other reactants.
Annealing or hybridization in the present invention is performed under stringent conditions that allow for specific binding between the primer and the target nucleotide sequence. Such stringent conditions for annealing will be sequence-dependent and varied depending on environmental parameters.
Amplified cDNA of the nucleotide of SEQ ID NO:1 is analyzed by suitable methods to measure the expression level. For example, the resulting products are separated by gel electrophoresis and the band patterns are analyzed.
The analysis for evaluating the expression amounts of β-PIX protein may be conducted in accordance with immunoassay methods known to one skilled in the art. The immunoassay format includes, but is not limited to, radioimmunoassay, radioimmuno-precipitation, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry assay, immunofluorescence staining assay and immunoaffinity assay.
The immunoassay or immunostaining procedures can be found in Enzyme Immunoassay, E. T. Maggio, ed., CRC Press, Boca Raton, Fla., 1980; Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology, Vol. 1, Walker, J. M. ed., Humana Press, NJ, 1984; and Ed Harlow and David Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999.
For example, according to the radioimmunoassay method, the radioisotope (e.g., C14, I125, P32 and S35) labeled antibody may be used to detect the β-PIX protein.
According to the ELISA method, the specific example of the present method may further comprise the steps of: (i) coating a surface of a solid substrate with a cell lysate of interest; (ii) incubating the cell lysate to be analyzed with β-PIX protein as a primary antibody; (iii) incubating the resultant of step (ii) with a secondary antibody conjugated to an enzyme; and (iv) measuring the activity of the enzyme.
The solid substrate coated with the primary antibody is a hydrocarbon polymer (e.g., polystyrene and polypropylene), a glass, a metal or a gel, and most preferably, a microtiter plate.
The secondary antibody conjugated to an enzyme includes, but is not limited to, an enzyme catalyzing colorimetric, fluorometric, luminescence or infra-red reactions, for example, alkaline phosphatase, β-galactosidase, horseradish peroxidase, luciferase and cytochrome P450. Where using alkaline phosphatase, bromochloroindolylphosphate (BCIP), nitro blue tetrazolium (NBT) and ECF (enhanced chemifluorescence) may be used as a substrate; in the case of using horseradish peroxidase, chloronaphtol, aminoethylcarbazol, diaminobenzidine, D-luciferin, lucigenin (bis-N-methylacridinium nitrate), resorufin benzyl ether, luminol, Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine, Pierce), HYR (p-phenylenediamine-HCl and pyrocatechol), TMB (3,3,5,5-tetramethylbenzidine), ABTS (2,2′-Azine-di[3-ethylbenzthiazoline sulfonate]), o-phenyldiamine (OPD) and naphtol/pyronin, glucose oxidase and tNBT (nitroblue tetrazolium) and m-PMS (phenzaine methosulfate) may be used as a substrate.
According to the capture-ELISA method, the specific example of the present method may comprise the steps of: (i) coating a surface of a solid substrate with an antibody of the β-PIX protein as a capturing antibody; (ii) incubating the capturing antibody with a cell sample; (iii) incubating the resultant of step (ii) with a detecting antibody having a fluorescent label which reacts with the β-PIX protein specifically; and (iv) measuring the signal generated from the label.
The detecting antibody includes a substance generating a detectable signal. The signal-generating substance bound to antibody includes, but is not limited to, chemical (e.g., biotin), enzyme (alkaline phosphatase, β-galactosidase, horseradish peroxidase and Cytochrome P450), radio-isotope (e.g., C14, I125, P32 and S35), fluorescent (e.g., fluoresin), luminescent, chemiluminescent and FRET (fluorescence resonance energy transfer) substances. Various methods for labels and labelings are described in Ed Harlow and David Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1999.
The analysis for measuring the activity or the signal of final enzyme in the ELISA and capture-ELISA method may be carried out by various methods known to those skilled in the art. The signal detection permits to a quantitative or qualitative analysis of the β-PIX protein. For example, the signal of each biotin- and luciferase-labeled protein may be feasibly detected using streptavidin and luciferin.
The migration potential of a stem cell may be predicted by analyzing the final strength of the signal obtained by above-mentioned immunoassay processes.
In addition, western blot analysis or immunocellularchemical assay with β-PIX specific antibodies may also be performed. Concretely, transformed cells are incubated with anti-β-PIX monoclonal antibodies and then incubated with secondary antibodies conjugated with labels such as tetramethylrhoodamine isothiocyanate (TRITC). Thereafter, the intensity of label detection is compared with negative controls to evaluate the expression level of β-PIX.
If the expression level of the nucleotide of SEQ ID NO:1 in the stem cells to be analyzed is measured to be lower than normal stem cells, they are determined to lack the migration potential (or cell therapeutic efficacy)
In still another aspect of this invention, there is provided a method for screening an adjuvant for cell therapy improving the migration potential of a stem cell to treat neurological diseases, comprising the steps of:
(a) contacting a test substance to a cell comprising the nucleotide sequence of SEQ ID NO:1; and
(b) measuring the expression level of the nucleotide of SEQ ID NO:1, wherein when the expression level of the nucleotide of SEQ ID NO:1 is increased, the test substance is determined the adjuvant for cell therapy improving the migration potential of the stem cell to treat neurological diseases.
According to the present method, the cells containing the nucleotide of SEQ ID NO:1 are first contacted to test substances to be analyzed. Preferably, the cells of the present method are human stem cells, and most preferably, human mesenchymal stem cells. The term “substance” used herein in conjunction with the present screening method refers to a material to be tested in the present method for analyzing its influence on the expression level of the nucleotide of SEQ ID NO:1. The substance includes chemical compounds, peptides, antibody proteins, nucleotides, antisense-RNA, siRNA (small interference RNA) and extract of natural source, but not limited to.
Afterwards, the expression level of the nucleotide sequence of SEQ ID NO:1 is measured. Where the expression level of the nucleotide sequence of SEQ ID NO:1 is measured to be increased, the substance is determined the adjuvant for cell therapy improving the migration potential of a stem cell to treat neurological diseases.
The features and advantages of the present invention will be summarized as follows:
(a) The present invention provides a composition for improving the migration potential of a stem cell, a method for evaluating the migration potential of a stem cell and a method for screening an adjuvant for cell therapy improving the migration potential of a stem cell.
(b) The present invention may be effectively used for enhancing the efficacy of neurological disease-treatment by inducing therapeutic stem cells to migrate efficiently to the lesion site.
The present invention will now be described in further detail by examples. It would be obvious to those skilled in the art that these examples are intended to be more concretely illustrative and the scope of the present invention as set forth in the appended claims is not limited to or by the examples.
EXAMPLES
Materials and Methods
1. Animal Preparation and Ischemic Surgery.
All animal procedures were performed in accordance with the Hanyang University guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of Hanyang University. Sprague-Dawley (SD) rats, weighing 210 to 245 g, were purchased from Biogenomics Inc. (Seoul, Korea).
After periods of adaptation and pretraining for behavioral tests, the left middle cerebral arteries (MCA) of 95 SD rats weighing 295 to 360 g were occluded for two hours using the intraluminal filament technique described in our previous study (1, 2). Throughout and following the surgery, rats were deeply anesthetized by intraperitoneal injection of tiletamine (25 mg/kg) and zolazepam (25 mg/kg, Zoletil, Yuhan Corp., Seoul, Korea) together with xylazine (10 mg/kg, Rompun, Bayer, Frankfurt, Germany) and body temperature was maintained at 36.6±0.5° C. with a thermistor-controlled heating pad. Physiological variables (pH, pCO2, pO2 and hematocrit) were measured in 0.1 ml aliquots of arterial blood obtained from a right femoral catheter using a blood-analysis system (International Technidyne, NJ, USA). Arterial pressure was monitored from the arterial catheter with a strain-gauge transducer (LIFE KIT DX-360; Nihon Kohden, Tokyo, Japan) and amplifier (MacLab Bridge Amplifier, ADInstruments Pty Ltd., Castle Hill, Australia). Phasic pressure, mean arterial pressure (MAP), and heart rate (HR) were recorded at a sampling rate of 200/s using a data acquisition system and laboratory computer (MacLab 8 analog-to-digital converter and Macintosh Computer). For the cerebral blood flow (CBF) study, a wire-type probe (0.3 mm diameter; Unique Medical, Tokyo, Japan) connected to a Laser Doppler flow meter (ALF21; Advance, Tokyo, Japan) was inserted 6 mm through a small burr hole placed 2 mm lateral to the bregma, such that the probe lay against the dural surface overlying the frontal cortex. Measurements were taken at a depth of 6 mm from the cortex to evaluate the deep ischemic core regions (caudate and putamen of the affected hemisphere).
After a 2-h occlusion, reperfusion was performed as described in our previous reports (1, 3).
A sham surgery was performed in additional 10 rats by introducing and immediately withdrawing a thread into the left common carotid artery. Other procedures in the sham group were identical to those used in the ischemic surgery.
2. Labeling of MSCs with Feridex and Protamine Sulfate.
The commercially available Feridex IV (TAEJOON Pharmaceutical Co., Ltd., Seoul, Korea Mfd by Advanded Managnetics, Inc. Combridge, Mass., USA)) has a total iron content of 11.2 mg/mL (11.2 iron μg/μL). Protamine sulfate (Sigma, USA) was prepared as a fresh stock solution of 1 mg/mL in distilled water at the time of use. Feridex IV at a concentration of 25 μg/mL was put into a tube containing serum-free DMEM medium (Gibco invitrogen, Carlsbad, Calif., USA) containing 100 unit/ml penicillin and 100 mg/ml streptomycin. Protamine sulfate was then added to the solution at 1 ug/ml concentrations. The solution (FE-Pro complexes) containing feridex IV and protamine sulfate was mixed for 60 minutes. And then, the solution was added to the adherent hMSC cell culture. FE-Pro complexes were added directly to the cells, incubated for 2 hours, and then an equal volume of the complete medium was added to the cells. The cell was then incubated overnight.
3. MSCs Grafting in Ischemic Stroke Model Rats.
To examine whether the migratory activity of implanted MSCs differs according to their origin, 4 kinds of MSCs such as ALS-MSCs from ALS patients (IRB-No), C-MSCs purchased from Cambrex, UCB-MSCs from umbilical cord blood (IRB-No), and hUC-MSCs from the endothelial/subendothelial layer of human umbilical cord (IRB-No) were injected into each 18 SD rats using stereotaxic surgery (ALS-MSC, C-MSC, UCB-MSC, and hUC-MSC groups, respectively) two weeks after intraluminal left MCA occlusion (MCAo). An equivalent volume of PBS was similarly injected into the remaining 18 rats (PBS group). All these groups were not statistically different in body weight (from 317.3±22.0 g to 324.3±14.1 g) or motor and behavioral deficit score (from 6.6±0.7 to 7.0±0.8) just before the implantation. The animals were anesthetized with pentobarbital sodium (50 mg/kg, IP). We implanted 5 μl suspensions of 6×105 each kind of MSCs, and PBS in one site contralateral (Site: AP=+0.7, R=+2, V=−5.5) to the lesion. The suspensions were delivered in 2 min, and the syringe was then left in place for an additional 2 min. For the control group, 5 μl of PBS was used. The rats in both groups received daily immunosuppression with cyclosporine A (10 mg/kg body weight, subcutaneously; Sandoz, Switzerland) from two days before cell transplantation until the end of the study.
4. Behavioral Tests of Ischemic Stroke Model Rats.
All animals were trained for neurobehavioral assessment for seven days before MCAO. The neurologic examination was performed daily to assess a neurologic deficit score (NDS) comprised of consciousness (0, normal; 1, restless; 2, lethargic; 3, stuporous; 4, death), gait (0, normal; 1, paw adduction; 2, unbalanced walking; 3, circling; 4, unable to stand; 5, no movement), limb tone (0, normal; 1, spastic; 2, flaccid), and pain reflex (0, normal; 2, hypoactive; 4, absent) at 2 hrs and 7, 14 (just before implantation), 21, 28, and 35 days after MCAO by an investigator who was blind to the experimental groups (4).
5. In Vivo MRI Study
In MRI studies, all the rats were anesthetized with pentobarbital sodium (50 mg/kg IP) and fixed to a Taoka rat cradle. They maintained respiration without assistance. A 3-inch-diameter circular receive-only surface coil was plated under the head of each rat, with the center of the coil located at the midpoint of the midline between the ear-ear and eye-eye lines. Body temperature was kept at 37° C. with a heating pad. The temperature of the MR imaging room was controlled to roughly 27° C., and MR imaging was performed with 3T clinical instrument (Philips, Netherland) with animal coil (Shanghai Chenguang Medical TechnologiesCo., LTD, China). For the elucidation of the extent of ischemic lesion, Fluid Attenuated Inversion Recovery (FLAIR) images were obtained using the spin-echo technique (TR=11,000 ms and TE=125 ms) between the vertex of the head and the bottom of the brain. Other imaging parameters included 0.7 mm slice thickness, point resolution of 284×286 μm and number of acquisitions=1. For T2* weighted images of a rat brain with Multiplanar Gradient-Recalled (MPGR) pulse sequence, the following parameters were adopted: TR=596 ms, TE=16 ms, section thickness=0.7 mm, point resolution: 292×290 μm and number of acquisitions=1.
6. Immunohistochemistry of Human Mitochondria.
To confirm whether the low signal intensities shown the MPGR images are due to the implanted MSCs, we sacrificed three rats from the C-MSC group 35 days after the implantation. Anti-human mitochondria monoclonal antibody (1:100, Chemicon, Temecula, Calif., USA) was used as a primary antibody. Coronal sections (20 μm thickness) of the brain were prepared and incubated with one of the primary antibody for 72 hours at 4° C. The sections were washed three times for 5 min each to remove unbound antibodies and then incubated for 24 hours with the appropriate secondary antibody conjugated to TRITC. Unbound secondary antibody was removed with three rinses of 5 min each. After air-drying, coverslip was applied to the slides with Vector Shield mounting medium. As a negative control, the above procedures were repeated without primary antibodies. Cell staining was not observed in the negative control.
A laser-scanning confocal microscopy system mounted onto a LEICA DMIRE2 microscope (Germany) was used. For immunofluorescence-labeled slides, red (TRITC) fluorochromes on the slides were excited by the laser beam at 557-nm, and emissions were acquired sequentially with a photomultiplier tube through 576-nm emission filters, respectively. The implanted stem cells were stained with antibody for human mitochondria.
7. Production and Propagation of the Recombinant Lentivirus.
To confirm the role of β-PIX in the migration of stem cells in vivo, we used lentiviral DNAs bearing the β-PIX specific shRNA or cDNA. The lentiviral DNA containing the shRNA were purchased from Open biosystems with Trans-LentivireTM GIPZ packaging System (OpenBiosystem, USA). The viral stocks were produced following the manufacturer's instructions. For β-PIX gene over-expression, the β-PIX and GFP cDNAs were subcloned into the pLenti6/V5-D-TOPO (Invitrogen, USA) and confirmed by sequencing. The recombinant β-PIX- or GFP-Lentivirus was produced following the manufacturer's instructions (Invitrogen, USA) with minor modification. To determine viral concentration of the viral stocks, the viral supernatants were serial diluted and transduced into hBM-MSC or HT1080 cells with 6 μg/ml Polybrene (Sigma, USA) and then cells were selected by 6 μg/ml Blasticidin (Invitrogen, USA) (M. Kimura et al., 1994) for 10 days. The remaining cells were stained with crystal violet and colonies were counted under the microscopy. For the lentivirus carrying GFP gene, the virus was transduced into hBM-MSCs following the described above. GFP-transduced hBM-MSCs were growth for 3 days and fixed in 1% paraformaldehyde and the fluorescence activities are read using by FACS machine. We obtained 6×105 TU (transduction unit)/ml of β-PIX gene-transduced viral particals in HT1080 cell, 2×105 TU/ml in hBM-MSCs and 1×105 TU/ml of the shRNA-transduced viral particals in hBM-MSCs. To obtain the high concentration of recombinant virus, the virus-containing supernatants were harvested using ultracentrifugation at 28,000 g for 90 min and stored −80° C.
8. Lentiviral Infection.
hBM-MSCs were seeded at a density of 8×105 cells per 75T flasks. MSCs were exposed to 0, 2 or 5 multiplicity of infection (MOI) of the infectious viral particles containing the shRNA, GFP or β-PIX gene in 15 ml DMEM media at 37° C. for overnight and the media were removed and cells washed once with DMEM. The cells were then incubated for 4 days with normal medium, and alteration of migratory activity in β-PIX gene-modified MSCs was evaluated in vitro and in vivo condition by using the above described methods.
9. Cell Migration Assay.
Cell migration was examined by a QCM chemotaxis (8 μm pore size) 96-well migration assay (Chemicon, USA). Briefly, the migration chambers were coated with 50 μl of HA (5 mg/ml) and air-dried overnight. 5×104 MSCs in 100 μl serum-free medium were seeded in the migration chamber. The lower chamber contained 150 μl of serum-free medium containing 10% bovine serum albumin. The plates were incubated at 37° C. in 5% CO2 for 24 hrs. After incubation, MSCs suspended in media in the migration chamber were gently removed by flipping out the medium. The cells adhering to the top side of the membrane were removed by scratching with a cotton applicator, and the migration chamber plate was then placed onto a new 96-well feeder tray containing 150 μl of prewarmed cell detachment solution in the wells. After 30 minutes of incubation at 37° C., 50 μl of a lysis buffer/dye solution was added to the feeder tray and incubated 15 minutes at room temperature. The mixture (150 μl) was then transferred to a new 96-well plate and the plate was read with a fluorescence plate reader using a 480/520-nm filter set (HTS 7000 Bioassay reader), which was performed according to the manufacturer's instructions (5).
10. Real Time PCR and Reverse Transcription-Polymerase Chain Reaction (RT-PCR).
To investigate the difference of the level of mRNA for β-PIX, four kinds of MSCs such as ALS-MSCs, C-MSCs, UCB-MSCs, and hUC-MSCs were harvested at near confluence, and total RNAs were extracted using Trizol reagent following the manufacturer's instructions (Invitrogen, USA). 5 μg total RNA was reverse-transcribed using RevertAidTM M-MuLV reverse transcriptase (MBI Fermentas, USA), 0.2 μg random primer (Invitrogen, USA), 1 mM dNTPs, and the supplied buffer. The first strand cDNA was amplified using Taq DNA polymerase (MBI Fermentas, MD) with 5′-AAGCGCAAACCTGAACGGAA-3′ (upstream) and 5′-TCACCTCAGAACTGGTCTTCA-3′ (downstream) as primers for β-PIX and 5′-TGCTATCCCTGAAAGCCTCTG-3′ (upstream) and 5′-AGCTGGGGTGATGAAGCTGTA-3′ (downstream) primers for β-actin. For cloning human β-PIX gene, the first strand cDNA from wild type MSCs was amplified using PyrobestTM DNA polymerase (TaKaRa, Japan) with primers 5′-CACCATGACCGATAATAGCAACAA -3′ (forward) and 5′-TCACCTCAGAACTGGTCTTCA-3′ (reverse). The PCR cycling parameters were as follows: initial denaturation at 94° C. for 2 min; 30 cycles of 30 s at 94° C. for denaturation, 30 s at 55° C. for primer annealing, and 1 min at 72° C. for extension; and final extension at 72° C. for 10 min. After amplification, the PCR products were resolved by agarose gel electrophoresis. For quantification of gene transcripts, real time PCR was performed in 96-well plates, with a final volume of 20 μl/well using the SYBR Green PCR kit (Applied Biosystems, Inc., Foster City, Calif., USA). Each reaction volume contained 10 μl of SYBR Green mix (2× concentrated), 6 μl of H2O, 1 μl of cDNA sample, and 3 μl of primer mix (sense and antisense primers, each 2 pmol/μl). The real time PCR cycling parameters were as follows: initial denaturation at 95° C. for 10 min; 40 cycles of 15 sec at 95° C. for denaturation, 1 min at 60° C. for primer annealing and extension. After the amplification protocol a dissociation curve was constructed by ramping the temperature from 60 to 90° C. The resulting Ct values were converted to absolute amounts of cDNA present in the sample (E-Ct) (37). To correct for differences in cDNA amounts between samples, we normalized the target PCR to the geometric mean values of PCRs on a set of reference genes.
11. Quantitative PCR Array.
Two plates of the RT2 Profiler PCR array for human tumor metastasis (PANS-028; SuperArray Bioscience Corporation, Frederick, Md., USA) were used to compare Q-PCR validated cDNA samples of normal- and ALS-MSCs. cDNA equivalent to 1 μg of total RNA was used for each plate. The cDNA was mixed with the RT2 SYBR Green/ROX Q-PCR Master Mix, and 25 μl was added to each of the wells containing different primers. The plate was run under the same conditions as described above. The outcome was normalized against the set of reference genes used for the Q-PCR. Analysis using the references genes present on the array yielded a comparable outcome.
12. Western Blotting and Immunocytochemistry.
To assess the difference of the protein level of β-PIX, western blot and immunocytochemistry were performed with a specific antibody for β-PIX (Cell signaling, USA).
First, western blot was performed with the antibody (1:1000) according to previously described procedures (28). 5×106 MSCs cultured for 24 hrs were used for western blot. All figures are representative of at least five independent experiments. And then, immnucytochemistry was performed. After culture for 24 hrs, the cells were washed with PBS and fixed with 4% paraformaldehyde in PBS for 20 min at 4° C. Following several washes, the cells were permeabilized with 0.5% Triton X-100 for 20 min. After incubation in 5% BSA in PBS for one hour, the cells were reacted with anti-β-PIX monoclonal antibody (1:100) overnight at 4° C. Following incubation, the cells were washed three times for 5 min each to remove unbound antibodies and then incubated with the appropriate secondary antibody conjugated to TRITC for 20 min at room temperature. Unbound secondary antibody was removed by three rinses lasting 10 min each. The coverslip was overlaid with Vector Shield mounting medium (Vector Laboratories, CA, USA). As a negative control, the above procedures were also carried out with mouse IgG antibody (Kamiya Biomedical, WA, USA).
13. Comparison of Neurotrophic Factors.
The present inventors hypothesized that reduced β-PIX expression could decrease the secretion of neurotrophic factors that are important for the improvement of motor functions by MSCs. A total of 1×104 ALS-MSCs or C-MSCs were plated in 96-well plates. After incubation for 24 hrs, each culture supernatant was divided into 200 μL triplicate samples. Vascular endothelial growth factor (VEGF), stromal cell-derived factor-1α (SDF-1α), and brain-derived neurotrophic factor (BDNF) levels were measured in the culture supernatants with BDNF, SDF-1α, and VEGF ELISA kits (R&D Systems, USA) by following the manufacturer's instructions (2). When compared with C-MSCs, concentrations of SDF-1α (A) and VEGF (B) were significantly decreased in culture supernatant of ALS-MSCs but concentration of BDNF (C) was not. The level of these neurotrophic factors is not affected by genetic modulation of β-PIX.
Results
1. Comparison of Migratory Capacity of MSCs Derived from Different Origins.
We followed the migration of Ferumoxides-labeled MSCs in rat brains using in vivo MR imaging. MSCs were derived from different origins including amyotrophic lateral sclerosis patient bone marrow (ALS-MSC), normal human bone marrow of which MSCs were purchased from Cambrex® (C-MSC), human umbilical cord tissue (hUC-MSC), and umbilical cord blood (UCB-MSC). The path of migratory MSCs in T2*-weighted images of the ischemic rat brain can be easily tracked by observing the hypointense voxels (i.e., dark regions) (FIG. 5). Surprisingly, the ALS-MSC lacked migratory capability, while all other MSC populations migrated to the lesion sites (FIG. 1a). Out of 10 rats in each group, hypointense voxels were detected in seven rats of the C-MSC group, eight of the hUC-MSC group, nine of the UCB-MSC group, and only one of the ALS-MSC group. This negates the assumption in the field of MSC transplantation that all sources of MSCs possess migratory capacity in the brain. The migratory behaviours of ALS-MSC and C-MSCs in MSC-implanted rat brains were followed up to 35 days after transplantation and after 35 days, the ALS-MSCs did not show migratory activity compared to C-MSCs (FIG. 1b).
The results of the MR studies for the in vivo migratory capacity of different MSC populations was also corroborated by in vitro transwell chemotaxis assays as shown in FIG. 1c. Moreover, the recovery of motor function of rats with ischemic stroke that were implanted with C-MSCs, hUC-MSCs, or UCB-MSCs significantly improved, while ALSMSCs failed to support motor function improvement (FIG. 6).
2. Behavioral Tests of Ischemic Stroke Model Rats.
A decrease in the neurologic deficit score (NDS) indicates an improvement in behavioral functions. As shown in FIG. 6, there was no difference between the five groups prior to implantation, but the NDS was significantly lower in the C-MSC, hUC-MSC, and UCB-MSC groups (N=10 in each group) than in the ALS-MSC group (N=10) from 7 days after implantation although statistically significant difference was shown from 21 days after implantation. In other words, C-MSCs, hUC-MSCs, and UCB-MSCs significantly improved behavioral functions of ischemic stroke rats but ALS-MSCs did not.
3. Quantitative PCR Array.
Quantitative PCR was used to identify genes that are necessary for cancer cell migration and play a role in MSC migration to lesion sites (FIG. 7). The expression of genes such as VEGFA, CTSK, β-PIX, and MTSS1 were markedly lower in ALS-MSCs than C-MSCs (FIG. 2a). VEGFA was used as internal control because it is known to be down-regulated in ALS patients (2). The β-PIX gene expression was reduced 7.58 fold, yet has no known functions in stem cell biology. Instead, it has established functions in T cell chemotaxis across reactive barriers (3), cancer cell migration (4), and neurite outgrowth (5).







TABLE 1







Names of migration associated genes which were investigated in this study










Unigene
GeneBank
Symbol
Description





Hs.158932
NM_000038 
APC
Adenomatous polyposis coli


Hs.100426
NM_015399
BRMS1
Breast cancer metastasis suppressor 1


Hs.251526
NM_006273
CCL7
Chemokine (C—C motif) ligand 7


Hs.502328
NM_000610
CD44
CD44 molecule (Indian blood group)


Hs.461086
NM_004360
CDH1
Cadherin 1, type 1, E-cadherin (epithelial)


Hs.116471
NM_001797
CDH11
Cadherin 11, type 2, OB-cadherin (osteoblast)


Hs.171054
NM_004932
CDH6
Cadherin 6, type 2, K-cadherin (fetal kidney)


Hs.512599
NM_000077
CDKN2A
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)


Hs.162233
NM_001273
CHD4
Chromodomain helicase DNA binding protein 4


Hs.508716
NM_001846
COL4A2
Collagen, type IV, alpha 2


Hs.143212
NM_003650 
CST7
Cystatin F (leukocystatin)


Hs.208597
NM_001328 
CTBP1
C-terminal binding protein 1


Hs.534797
NM_001903
CTNNA1
Catenin (cadherin-associated protein), alpha 1, 102 kDa


Hs.632466
NM_000396
CTSK
Cathepsin K


Hs.716407
NM_001912
CTSL1
Cathepsin L1


Hs.522891
NM_000609 
CXCL12
Chemokine (C—X—C motif) ligand 12 (stromal cell-derived factor 1)


Hs.593413
NM_003467 
CXCR4
Chemokine (C—X—C motif) receptor 4


Hs.22393
NM_003677
DENR
Density-regulated protein


Hs.523329
NM_004442 
EPHB2
EPH receptor B2


Hs.434059
NM_001986 
ETV4
Ets variant 4


Hs.374477
NM_005243
EWSR1
Ewing sarcoma breakpoint region 1


Hs.481371
NM_005245
FAT1
FAT tumor suppressor homolog 1 (Drosophila)


Hs.165950
NM_002011
FGFR4
Fibroblast growth factor receptor 4


Hs.646917
NM_002020
FLT4
Fms-related tyrosine kinase 4


Hs.203717
NM_002026
FN1
Fibronectin 1


Hs.333418
NM_014164
FXYD5
FXYD domain containing ion transport regulator 5


Hs.82963 
NM_000825
GNRH1
Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone)


Hs.208229
NM_032551
KISS1R
KISS1 receptor


Hs.396530
NM_000601
HGF
Hepatocyte growth factor (hepapoietin A; scatter factor)


Hs.44227 
NM_006665
HPSE
Heparanase


Hs.37003 
NM_005343
HRAS
V-Ha-ras Harvey rat sarcoma viral oncogene homolog


Hs.90753 
NM_006410
HTATIP2
HIV-1 Tat interactive protein 2, 30 kDa


Hs.160562
NM_000618
IGF1
Insulin-like growth factor 1 (somatomedin C)


Hs.83077 
NM_001562
IL18
Interleukin 18 (interferon-gamma-inducing factor)


Hs.126256
NM_000576
IL1B
Interleukin 1, beta


Hs.846 
NM_001557
IL8RB
Interleukin 8 receptor, beta


Hs.524484
NM_002206
ITGA7
Integrin, alpha 7


Hs.218040
NM_000212
ITGB3
Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)


Hs.527778
NM_002231
CD82
CD82 molecule


Hs.95008 
NM_002256 
KISS1
KiSS-1 metastasis-suppressor


Hs.505033
NM_004985
KRAS
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog


Hs.449909
NM_002295
RPSA
Ribosomal protein SA


Hs.599039
NM_006500
MCAM
Melanoma cell adhesion molecule


Hs.484551
NM_002392
MDM2
Mdm2 p53 binding protein homolog (mouse)


Hs.132966
NM_000245
MET
Met proto-oncogene (hepatocyte growth factor receptor)


Hs.444986
NM_006838
METAP2
Methionyl aminopeptidase 2


Hs.651869
NM_002410
MGAT5
Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase


Hs.2258
NM_002425
MMP10
Matrix metallopeptidase 10 (stromelysin 2)


Hs.143751
NM_005940
MMP11
Matrix metallopeptidase 11 (stromelysin 3)


Hs.2936
NM_002427
MMP13
Matrix metallopeptidase 13 (collagenase 3)


Hs.513617
NM_004530
MMP2
Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase,





72 kDa type IV collagenase)


Hs.375129
NM_002422 
MMP3
Matrix metallopeptidase 3 (stromelysin 1, progelatinase)


Hs.2256
NM_002423
MMP7
Matrix metallopeptidase 7 (matrilysin, uterine)


Hs.297413
NM_004994
MMP9
Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV





collagenase)


Hs.525629
NM_004689
MTA1
Metastasis associated 1


Hs.700429
NM_014751
MTSS1
Metastasis suppressor 1


Hs.202453
NM_002467
MYC
V-myc myelocytomatosis viral oncogene homolog (avian)


Hs.437922
NM_005376
MYCL1 
V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian)


Hs.187898
NM_000268
NF2
Neurofibromin 2 (merlin)


Hs.118638
NM_000269
NME1
Non-metastatic cells 1, protein (NM23A) expressed in


Hs.463456
NM_002512
NME2
Non-metastatic cells 2, protein (NM23B) expressed in


Hs.9235
NM_005009
NME4
Non-metastatic cells 4, protein expressed in


Hs.279522
NM_006981
NR4A3
Nuclear receptor subfamily 4, group A, member 3


Hs.466871
NM_002659
PLAUR
Plasminogen activator, urokinase receptor


Hs.409965
NM_002687
PNN
Pinin, desmosome associated protein


Hs.500466
NM_000314 
PTEN
Phosphatase and tensin homolog


Hs.408528
NM_000321
RB1
Retinoblastoma 1


Hs.494178
NM_006914
RORB
RAR-related orphan receptor B


Hs.436687
NM_003011
SET
SET nuclear oncogene


Hs.12253 
NM_005901
SMAD2
SMAD family member 2


Hs.75862 
NM_005359
SMAD4
SMAD family member 4


Hs.195659
NM_005417
SRC
V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)


Hs.514451
NM_001050
SSTR2
Somatostatin receptor 2


Hs.371720
NM_003177
SYK
Spleen tyrosine kinase


Hs.475018
NM_005650
TCF20
Transcription factor 20 (AR1)


Hs.645227
NM_000660
TGFB1
Transforming growth factor, beta 1


Hs.633514
NM_003255
TIMP2
TIMP metallopeptidase inhibitor 2


Hs.644633
NM_000362
TIMP3
TIMP metallopeptidase inhibitor 3


Hs.591665
NM_003256
TIMP4
TIMP metallopeptidase inhibitor 4


Hs.478275
NM_003810
TNFSF10
Tumor necrosis factor (ligand) superfamily, member 10


Hs.654481
NM_000546
TP53
Tumor protein p53


Hs.155942
NM_002420
TRPM1
Transient receptor potential cation channel, subfamily M, member 1


Hs.160411
NM_000369
TSHR
Thyroid stimulating hormone receptor


Hs.73793
NM_003376
VEGFA
Vascular endothelial growth factor A


Hs.534255
NM_004048
B2M
Beta-2-microglobulin


Hs.412707
NM_000194
HPRT1
Hypoxanthine phosphoribosyltransferase 1


Hs.523185
NM_012423
RPL13A
Ribosomal protein L13a


Hs.592355
NM_002046
GAPDH
Glyceraldehyde-3-phosphate dehydrogenase





β-PIX


Hs.520640
NM_001101
ACTB
Actin, beta


N/A
SA_00105
HGDC
Human Genomic DNA Contamination


N/A
SA_00104
RTC
Reverse Transcription Control


N/A
SA_00104
RTC
Reverse Transcription Control


N/A
SA_00104
RTC
Reverse Transcription Control


N/A
SA_00103
PPC
Positive PCR Control


N/A
SA_00103
PPC
Positive PCR Control


N/A
SA_00103
PPC
Positive PCR Control









4. Analysis of Cell Migration According to β-PIX Expression.

To determine whether β-PIX is required for MSC migration, we prepared C-MSCs with β-PIX knockdown by lentiviral-transduced shRNA, and ALS-MSCs ectopically expressing β-PIX The knockdown model had reduced levels of β-PIX mRNA and protein (FIG. 3a). β-PIX was over-expressed in ALS-MSCs transduced with lentiviral DNAs bearing the β-PIX cDNAs PIX (FIG. 3b). The changes in β-PIX expression levels did not affect the MSC surface marker CD45-CD34-CD29+CD73+CD105+CD44+HLA-DR-phenotype (FIG. 8). However, the ALS-MSCs with over-expressed β-PIX had restored migratory capacity, whereas the β-PIX knockdown C-MSCs had drastically reduced migratory capacity as determined by an in vitro transwell chemotaxis assay (FIG. 3c). These results establish β-PIX as a facilitator of MSC migration.
We next examined the in vivo migration of ALS-MSCs over-expressing β-PIX and CMSCs with β-PIX knockdown. These MSCs were implanted into rat brains subjected to ischemic stroke. T2*-weighted images of rat brains confirmed the in vitro finding that β-PIX expression is necessary for MSC migration (FIG. 4a-4b). The β-PIX knockdown CMSCs showed much lower levels of migration (2 out of 10) into the ischemic focus than CMSCs (8 of 10) (FIG. 4a). However, migration was enhanced by β-PIX over-expression in ALS-MSCs (7 of 10) and detected on MRI in comparison to ALS-MSCs (1 of 10) (FIG. 4b).
5. Western Blot and Immunocellularchemical Assay
We next determined whether β-PIX mRNA and protein expression levels were correlated with the migratory activity of MSCs using RT-PCR, immunoblotting, and immunohistochemistry (FIG. 2). The expression levels of β-PIX mRNA and protein were significantly higher in C-MSCs, UCB-MSCs, and hUC-MSCs than ALS-MSCs (FIG. 2b-2d). Thus decreased expression of β-PIX mRNA and protein was associated with decreased migratory capacity of MSCs.
6. Comparison of Behavioral Functions between β-PIX Knockdowned and Vehicle C-MSCs.
We next determined if the migration of the implanted MSCs into the lesion site improved motor function recovery for the ischemic stroke rats. The rats that received β-PIX knockdown C-MSCs did not demonstrate any neurological function recovery, whereas rats that received C-MSCs transplant did show improvement (FIG. 9). Moreover, rats that received β-PIX over-expressing ALS-MSCs did not improve neurological functions and was similar to ALS-MSCs transplant rats. These results suggested that the migration of the implanted MSCs was necessary, but insufficient, for the ability of MSC transplants to improve motor functions of ischemic stroke rats.
7. Comparison of Neurotrophic Factors.
We found that the levels of two neurotrophic factors, SDF-1α and VEGF, were significantly lower for ALS-MSCs than for C-MSCs (Supplementary FIG. 6A, 6B). However, β-PIX knockdown in C-MSCs or over-expression in ALS-MSCs did not affect SDF-1α or VEGF expression levels (FIG. 10a-10b). Thus, autologous ALS-MSC transplants would be expected to require both β-PIX over-expression and supplementation of neurotrophic factors such as SDF-1α and VEGF to restore stem cell migration toward lesion sites that is needed for the improvement of motor function.
References


    1. Graziano, A. et al., Concave pit-containing scaffold surfaces improve stem cell derived osteoblast performance and lead to significant bone tissue formation. PLoS ONE 2 (6), e496 (2007).
    2. Lambrechts, D. et al., VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34 (4), 383(2003).
    3. Volinsky, N., Gantman, A., and Yablonski, D., A Pak- and Pix-dependent branch of the SDF-1alpha signalling pathway mediates T cell chemotaxis across restrictive barriers. Biochem J 397 (1), 213 (2006).
    4. ten Klooster, J. P., Jaffer, Z. M., Chernoff, J., and Hordijk, P. L., Targeting and activation of Rac1 are mediated by the exchange factor beta-Pix. J Cell Biol 172 (5), 759 (2006).
    5. Shin, E. Y. et al., Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth. J Biol Chem 277(46), 44417(2002).
    6. Mazzini, L. et al., Stem cell treatment in Amyotrophic Lateral Sclerosis. J Neurol Sci 265 (1-2), 78 (2008).
    7. Kim, H. Y. et al., Efficacy and Safety of Autologous Bone Marrow-derived Mesenchymal Stem Cell Treatment in Patients with Amyotrophic Lateral Sclerosis. J Korean Neurol Assoc 27 (2), 163 (2009).
    8. Koh, S. H. et al., Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 1229, 233 (2008).
    9. Omura, T. et al., Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 37 (5), 1307 (2006).
    10. Ko, I. K. et al., In vivo MR imaging of tissue-engineered human mesenchymal stem cells transplanted to mouse: a preliminary study. Ann Biomed Eng 35 (1), 101 (2007).
    11. Arbab, A. S. et al., Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104 (4), 1217(2004).
    12. Koh, S. H. et al., Erythropoietin increases the motility of human bone marrow multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev (2009).

## Claims

1. A method for improving the migration potential of a mesenchymal stem cell, comprising introducing into the mesenchymal stem cell a gene delivery system that expresses a nucleotide sequence encoding β-PIX having the amino acid sequence of SEQ ID NO:2 in the mesenchymal stem cell, wherein expression of said nucleotide sequence improves the migration potential of said mesenchymal stem cell when compared to a mesenchymal stem cell that does not express said nucleotide sequence.

2. The method according to claim 1, wherein the nucleotide sequence is SEQ ID NO: 1.

3. The method according to claim 1, wherein the gene delivery system is a plasmid, a recombinant adenovirus, an adeno-associated virus (AAV), a retrovirus, a lentivirus, a herpesvirus, a vaccinia virus, a liposome or a niosome.

4. The method according to claim 3, wherein the gene delivery system is the lentivirus.